SEARCH

SEARCH BY CITATION

References

  • 1
    Paul LC. Chronic renal transplant loss. Kidney Int 1995; 47: 14911499.
  • 2
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605612.DOI: 10.1056/NEJM200003023420901
  • 3
    Paul LC, Hayry P, Foegh M et al. Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: joint proposal from the Fourth Alexis Carrel Conference on chronic rejection and accelerated arteriosclerosis in transplanted organs. Transplant Proc 1993; 25: 20222023.
  • 4
    Kasiske BL, Andany MA, Danielson B. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis 2002; 39: 762768.
  • 5
    Mauiyyedi S, Colvin RB. Pathology of Kidney Transplantation. In: MorrisPJ, ed. Kidney Transplantation. Oxford : W.B. Saunders Company; 2002: 343376.
  • 6
    Sijpkens YW, Joosten SA, Paul LC. Chronic rejection in renal transplantation. Transplant Rev 2003; 17: 118130.
  • 7
    Hamburger J, Crosnier J, Dormont J. Observations in patients with a well-tolerated homotransplanted kidney: possibility of a new secondary disease. Ann N Y Acad Sci 1964; 120: 558577.
  • 8
    Maryniak RK, First MR, Weiss MA. Transplant glomerulopathy: evolution of morphologically distinct changes. Kidney Int 1985; 27: 799806.
  • 9
    Habib R, Broyer M. Clinical significance of allograft glomerulopathy. Kidney Int Suppl 1993; 43: S9598.
  • 10
    Olsen TS. Pathology of allograft rejection. In: BurdickJF, RacusenLC, SolezK, WilliamsGM, eds. Kidney transplant rejection. Diagnosis and treatment. New York, Basel , Hong Kong : Marcel Dekker Inc; 1992: 333.
  • 11
    Andresdottir MB, Assmann KJ, Koene RA, Wetzels JF. Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. Am J Kidney Dis 1998; 32: 582588.
  • 12
    Suri DL, Tomlanovich SJ, Olson JL, Meyer TW. Transplant glomerulopathy as a cause of late graft loss. Am J Kidney Dis 2000; 35: 674680.
  • 13
    Sijpkens YW, Joosten SA, Wong M-C et al. Immunological risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65: 24092418.DOI: 10.1111/j.1523-1755.2004.00662.x
  • 14
    Vongwiwatana A, Gourishankar S, Campbell PM, Solez K, Halloran PF. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004; 4: 124129.DOI: 10.1046/j.1600-6143.2003.00294.x
  • 15
    Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 23712380.DOI: 10.1097/01.ASN.0000025780.03790.0F
  • 16
    Horita S, Nitta K, Kawashima M et al. C4d deposition in the glomeruli and peritubular capillaries associated with transplant glomerulopathy. Clin Transplant 2003; 17: 325330.DOI: 10.1034/j.1399-0012.2003.t01-1-00014.x
  • 17
    Bohmig GA, Exner M, Habicht A et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 10911099.
  • 18
    Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574582.
  • 19
    Collins AB, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 22082214.
  • 20
    Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334341.DOI: 10.1046/j.1523-1755.2001.00495.x
  • 21
    Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant 2001; 16: 897904.DOI: 10.1093/ndt/16.5.897
  • 22
    McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319326.DOI: 10.1097/00007890-200002150-00001
  • 23
    Miettinen A, Stow JL, Mentone S, Farquhar MG. Antibodies to basement membrane heparan sulfate proteoglycans bind to the laminae rarae of the glomerular basement membrane (GBM) and induce subepithelial GBM thickening. J Exp Med 1986; 163: 10641084.DOI: 10.1084/jem.163.5.1064
  • 24
    Van Den Born J, Van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH. A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 1992; 41: 115123.
  • 25
    Van Den Born J, Van den Heuvel LP, Bakker MA et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 1993; 43: 454463.
  • 26
    Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000; 57: 385400.
  • 27
    Groffen AJ, Ruegg MA, Dijkman H et al. Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 1998; 46: 1927.
  • 28
    Joosten SA, Van Dixhoorn MGA, Borrias MC et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002; 160: 13011310.
  • 29
    De Fijter JW, Van Den Wall Bake AW, Braam CA, Van Es LA, Daha MR. Immunoglobulin A subclass measurement in serum and saliva: sensitivity of detection of dimeric IgA2 in ELISA depends on the antibody used. J Immunol Methods 1995; 187: 221232.DOI: 10.1016/0022-1759(95)00188-8
  • 30
    Van den Heuvel LP, Van Den Born J, Van De Velden TJ et al. Isolation and partial characterization of heparan sulphate proteoglycan from the human glomerular basement membrane. Biochem J 1989; 264: 457465.
  • 31
    Seino J, Vd Wall Bake WL, Van Es LA, Daha MR. A novel ELISA assay for the detection of C3 nephritic factor. J Immunol Methods 1993; 159: 221227.DOI: 10.1016/0022-1759(93)90160-9
  • 32
    Van Den Born J, Van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH. Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: characterization and immunohistological application in human tissues. J Histochem Cytochem 1994; 42: 89102.
  • 33
    Heremans A, Van Der Schueren B, De Cock B et al. Matrix-associated heparan sulfate proteoglycan: core protein-specific monoclonal antibodies decorate the pericellular matrix of connective tissue cells and the stromal side of basement membranes. J Cell Biol 1989; 109(6 Pt 1): 31993211.DOI: 10.1083/jcb.109.6.3199
  • 34
    Van Den Born J, Van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH. Production and characterization of a monoclonal antibody against human glomerular heparan sulfate. Lab Invest 1991; 65: 287297.
  • 35
    Groffen AJ, Veerkamp JH, Monnens LA, Van den Heuvel LP. Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Nephrol Dial Transplant 1999; 14: 21192129.DOI: 10.1093/ndt/14.9.2119
  • 36
    Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998; 67: 609652.DOI: 10.1146/annurev.biochem.67.1.609
  • 37
    Groffen AJ, Buskens CA, Van Kuppevelt TH, Veerkamp JH, Monnens LA, Van den Heuvel LP. Primary structure and high expression of human agrin in basement membranes of adult lung and kidney. Eur J Biochem 1998; 254: 123128.DOI: 10.1046/j.1432-1327.1998.2540123.x
  • 38
    O'Toole JJ, Deyst KA, Bowe MA, Nastuk MA, McKechnie BA, Fallon JR. Alternative splicing of agrin regulates its binding to heparin alpha-dystroglycan, and the cell surface. Proc Natl Acad Sci USA 1996; 93: 73697374.DOI: 10.1073/pnas.93.14.7369
  • 39
    Burgess RW, Skarnes WC, Sanes JR. Agrin isoforms with distinct amino termini: differential expression, localization, and function. J Cell Biol 2000; 151: 4152.
  • 40
    Raats CJ, Bakker MA, Hoch W et al. Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 1998; 273: 1783217838.DOI: 10.1074/jbc.273.28.17832
  • 41
    Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348: 25432556.DOI: 10.1056/NEJMra022296
  • 42
    Borza DB, Hudson BG. Molecular characterization of the target antigens of anti-glomerular basement membrane antibody disease. Springer Semin Immunopathol 2003; 24: 345361.DOI: 10.1007/s00281-002-0103-1
  • 43
    Leinonen A, Netzer KO, Boutaud A, Gunwar S, Hudson BG. Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain. Kidney Int 1999; 55: 926935.DOI: 10.1046/j.1523-1755.1999.055003926.x
  • 44
    Shu KH, Lu YS, Chang CH et al. Transplant glomerulopathy-a clinicopathological study. Transplant Proc 1996; 28: 15271528.